SENATE FLOOR VERSION - HB2748 SFLR Page 1
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
SENATE FLOOR VERSION
April 12, 2023
AS AMENDED
ENGROSSED HOUSE
BILL NO. 2748 By: Miller, Conley, West
(Tammy), Hasenbeck, Stark,
Townley, Roe, Baker,
Provenzano, Munson,
Crosswhite Hader, Hefner,
Schreiber, Ranson, Goodwin,
and Fugate of the House
and
Stanley of the Senate
[ public health and safety - step therapy
requirements - coverage - effective date ]
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
SECTION 1. NEW LAW A new section of law to be codified
in the Oklahoma Statutes as Secti on 7320 of Title 63, unless there
is created a duplication in numbering, reads as follows:
For the purpose of prohibiting step the rapy requirements for
certain prescription drugs to treat advanced metastatic cancer and
associated conditions.
As used in this section:
1. "Associated conditions" means the symptoms or side effects
associated with advanced metastatic cancer or its treatm ent and
SENATE FLOOR VERSION - HB2748 SFLR Page 2
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
which, in the judgment of the health care practitioner, will further
jeopardize the health of a patient if left untreated;
2. "Advanced metastatic cancer" means cancer that has spre ad
from the primary or original site of the cancer to nearby tissu es,
lymph nodes, or other areas or parts of the body.
SECTION 2. NEW LAW A new section of law to be co dified
in the Oklahoma Statutes as Section 7321 of Title 63, unless there
is created a duplication in numbering, reads as follows:
A. A health benefit plan that provides coverage for advanced
metastatic cancer and associated conditions may not require, be fore
the health benefit plan provides coverage of a prescriptio n drug
approved by the United States Food and Drug Administration, that the
enrollee:
1. Fails to successfully respond to a differe nt drug; or
2. Proves a history of failure of a different dr ug.
B. This section applies only to a drug, the use of which is:
1. Consistent with best practices for the treatment of advanced
metastatic cancer or an associated condition;
2. Supported by peer-reviewed, evidence-based literature; and
3. Approved by the United States Food and Drug Administration.
SECTION 3. This act shall become effective November 1, 2023.
COMMITTEE REPORT BY: COMMITTEE ON APPROPRIATIONS
April 12, 2023 - DO PASS AS AMENDED